Redx Pharma plc Update on Court Process (4892T)
October 13 2017 - 1:00AM
UK Regulatory
TIDMREDX
RNS Number : 4892T
Redx Pharma plc
13 October 2017
13 October 2017
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION
IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Permission granted for distribution to Unsecured Creditors
Redx, the drug discovery and development company, announces that
Jason Baker and Miles Needham of FRP Advisory LLP, joint
administrators of the Company and of its subsidiary, Redx Oncology
Limited ("Oncology") (together, the "Companies") have applied to
the High Court for an order which will enable the Companies to be
rescued as going concerns and the Joint Administrators to vacate
office.
Unless adjourned by the court, the application will be heard on
Thursday 26 October 2017. Assuming that the application is approved
by the High Court, the Joint Administrators will subsequently take
steps to return control of the Company to the directors, following
which the directors will seek to lift the suspension of the
Company's ordinary shares.
Further announcements will be made in due course.
For further information, please contact:
Redx Pharma Plc (in administration)
Contact for the Joint Administrators: T: + 44 203
Chris French 005 4000
James Rossiter
Cantor Fitzgerald Europe (Nomad & T: +44 20
Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Jason Baker and Miles Needham have been appointed as joint
administrators of Redx Pharma plc (in administration). The
company's affairs, business and property are being managed by the
joint administrators.
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDGGGPCUUPMGAP
(END) Dow Jones Newswires
October 13, 2017 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024